AstraZeneca has released phase 3 clinical trial information linking their newest asthma medication with reduced oral steroid use in patients with severe asthmatic symptoms. The drug, Benralizumab, shows a limited need for steroids, which according to an AstraZeneca statement, may cause weight gain, diabetes, anxiety, depression and osteoporosis. The FDA will be deciding the Benralizumab’s approval status during the fourth quarter of 2017. The drug is also being considered in Europe and Japan among other countries. Read the full press release here.